Pharmacological regulation of tissue fibrosis by targeting the mechanical contraction of myofibroblasts

The study demonstrated that (-)-blebbistatin (Ble), a non-muscle myosin Ⅱ inhibitor, significantly inhibited liver fibrosis in chronic injury mouse models by reducing tissue stiffness and myofibroblast activation. Ble's effects included decreasing the F/G-actin ratio and causing exnucleation of YAP1 and MRTF-A, which are involved in mechanical contraction. The research highlighted the potential of targeting mechanical contraction in myofibroblasts as a therapeutic strategy for fibrotic diseases, suggesting Ble's broad-spectrum antifibrotic effects across multiple organ fibrosis models.